N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine increases acetylcholine and decreases dopamine in mouse striatum: both responses are blocked by anticholinergic drugs.
The neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces neuropathology and clinical symptoms that resemble Parkinsonism in primates and humans. In mice it induces a long-lasting depletion of neostriatal 3,4-dihydroxyphenylethylamine (dopamine) content. Using the mouse, we found that MPTP induces a fall of dopamine and a rise of acetylcholine in the neostriatum. Both responses to MPTP can be blocked by prior treatment with atropine or trihexyphenidyl.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000109:Acetylcholine / Q000032:analysis*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D003342:Corpus Striatum / Q000032:analysis / Q000187:drug effects*; D004298:Dopamine / Q000032:analysis*; D008297:Male; D051379:Mice; D010276:Parasympatholytics / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D014282:Trihexyphenidyl / Q000494:pharmacology
D010276:Parasympatholytics; D011725:Pyridines; D014282:Trihexyphenidyl; D001285:Atropine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000109:Acetylcholine; D004298:Dopamine